Perimetry based on eye-movements in patients with ABI and Glaucoma - a screeningtest using eye tracking

Recruiting

Conditions: niet- aangeboren hersenletsel
Glaucoma
POAG. Acquired brain injury
Brain disease
10018307

Registration Number: NL-OMON49523

Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 220

Inclusion Criteria

Participant without vision loss (control participant; experiment O, A1)
-18 years or older.
• Informed written consent

Participant with Glaucoma (experiment A2):
•Diagnosed with glaucoma
•Reliable SAP (based on most recent SAP assessment, information in their
medical file).
•Age 50-70
•No cognitive impairments (MoCa score: score >= 24; TOSSA screening test score
> 5th percentile)
•Informed written consent

Participant with ABI (experiment A3):
•Diagnosed with acquired brain injury
•Cognitive impairment (CI), based on test scores regular care UMCG.
•Age:18-70
•Informed written consent.

Participant with ABI (experiment A4):
•Diagnosed with acquired brain injury
•Age 50-70
•Informed written consent.

Exclusion Criteria

Any of the following criteria will lead to exclusion from participation:

Participant without vision loss (healthy control participant; experiment O, A1)
•eye disease
•family history of glaucoma
•neurological disorder
•cognitive impairment: MoCa score: score < 24; TOSSA screening test score < 5th
percentile.

Participant with Glaucoma (A2)
-neurological disorder
-cognitive impairment: MoCa score: score < 24; TOSSA screening test score < 5th
percentile.

Participant with ABI (experiment A3):
•eye disease
•glaucoma

Participant with ABI (experiment A4):
•eye disease
•cognitive impairment: MoCa score: score < 24; TOSSA screening testscore < 5th
percentile.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main endpoints of the study are the validity and the test-retest<br /><br>reliability of the EMC-test:<br /><br>1. convergent validity: difference (dB) between the predicted MD (EMC) and the<br /><br>assessed MD (SAP), expressed as delta MD.<br /><br>2. test-retest reliability: the variability of the predicted MD (dB) between<br /><br>consecutive measurements in the same person</p><br>

Secondary Outcome Measures